Carmen Gil

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4254743/publications.pdf

Version: 2024-02-01

123 papers	6,725 citations	101496 36 h-index	66879 78 g-index
139 all docs	139 docs citations	139 times ranked	8639 citing authors

#	Article	IF	Citations
1	Organic Azides: An Exploding Diversity of a Unique Class of Compounds. Angewandte Chemie - International Edition, 2005, 44, 5188-5240.	7.2	1,894
2	COVID-19: Drug Targets and Potential Treatments. Journal of Medicinal Chemistry, 2020, 63, 12359-12386.	2.9	348
3	The recent impact of solid-phase synthesis on medicinally relevant benzoannelated nitrogen heterocycles. Bioorganic and Medicinal Chemistry, 2002, 10, 2415-2437.	1.4	268
4	Glycogen Synthase Kinase 3 Inhibition Promotes Adult Hippocampal Neurogenesis in Vitro and in Vivo. ACS Chemical Neuroscience, 2012, 3, 963-971.	1.7	139
5	Solid-Phase Synthesis of Biologically Active Benzoannelated Nitrogen Heterocycles: An Update. ACS Combinatorial Science, 2009, 11, 175-197.	3.3	131
6	Advances in the synthesis and recent therapeutic applications of 1,2,4-thiadiazole heterocycles. Bioorganic and Medicinal Chemistry, 2006, 14, 1644-1652.	1.4	128
7	Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases. Medicinal Research Reviews, 2011, 31, 924-954.	5.0	124
8	Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: Advances in the development of specific phosphodiesterase inhibitors. Medicinal Research Reviews, 2005, 25, 229-244.	5.0	111
9	Protein Kinase CK-1 Inhibitors As New Potential Drugs for Amyotrophic Lateral Sclerosis. Journal of Medicinal Chemistry, 2014, 57, 2755-2772.	2.9	95
10	Exploring the Binding Sites of Glycogen Synthase Kinase 3. Identification and Characterization of Allosteric Modulation Cavities. Journal of Medicinal Chemistry, 2011, 54, 8461-8470.	2.9	91
11	Switching Reversibility to Irreversibility in Glycogen Synthase Kinase 3 Inhibitors: Clues for Specific Design of New Compounds. Journal of Medicinal Chemistry, 2011, 54, 4042-4056.	2.9	84
12	Phosphodiesterase 7 Inhibition Preserves Dopaminergic Neurons in Cellular and Rodent Models of Parkinson Disease. PLoS ONE, 2011, 6, e17240.	1.1	83
13	Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease. Neurobiology of Aging, 2013, 34, 2133-2145.	1.5	77
14	cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases. Expert Opinion on Therapeutic Patents, 2014, 24, 1311-1321.	2.4	77
15	5-Imino-1,2,4-Thiadiazoles: First Small Molecules As Substrate Competitive Inhibitors of Glycogen Synthase Kinase 3. Journal of Medicinal Chemistry, 2012, 55, 1645-1661.	2.9	76
16	Benzyl Derivatives of 2,1,3-Benzo- and Benzothieno[3,2-a]thiadiazine 2,2-Dioxides:â€‰ First Phosphodiesterase 7 Inhibitors. Journal of Medicinal Chemistry, 2000, 43, 683-689.	2.9	74
17	Glycogen Synthase Kinase 3 Inhibitors in the Next Horizon for Alzheimer's Disease Treatment. International Journal of Alzheimer's Disease, 2011, 2011, 1-7.	1.1	69
18	Glycogen Synthase Kinase-3 Inhibitors as Potent Therapeutic Agents for the Treatment of Parkinson Disease.. ACS Chemical Neuroscience, 2013, 4, 350-360.	1.7	69

#	Article	IF	Citations
19	Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model. European Journal of Medicinal Chemistry, 2012, 47, 175-185.	2.6	64
20	Amyloid Î²-induced impairments on mitochondrial dynamics, hippocampal neurogenesis, and memory are restored by phosphodiesterase 7 inhibition. Alzheimer's Research and Therapy, 2018, 10, 24.	3.0	64
21	Î²-N-methylamino-l-alanine causes neurological and pathological phenotypes mimicking Amyotrophic Lateral Sclerosis (ALS): The first step towards an experimental model for sporadic ALS. Environmental Toxicology and Pharmacology, 2013, 36, 243-255.	2.0	60
22	PDE 7 Inhibitors: New Potential Drugs for the Therapy of Spinal Cord Injury. PLoS ONE, 2011, 6, e15937.	1.1	59
23	Non-ATP competitive glycogen synthase kinase 3Î² (GSK-3Î²) inhibitors: Study of structural requirements for thiadiazolidinone derivatives. Bioorganic and Medicinal Chemistry, 2008, 16, 495-510.	1.4	57
24	Synthesis, Structural Analysis, and Biological Evaluation of Thioxoquinazoline Derivatives as Phosphodiesteraseâ€...7 Inhibitors. ChemMedChem, 2009, 4, 866-876.	1.6	56
25	Dual inhibitor of PDE7 and GSK-3 â€“ VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice. Neuropharmacology, 2013, 64, 205-214.	2.0	56
26	Targeting TDP-43 phosphorylation by Casein Kinase-1Î´ inhibitors: a novel strategy for the treatment of frontotemporal dementia. Molecular Neurodegeneration, 2016, 11, 36.	4.4	55
27	Effect of Phosphodiesterase 7 (PDE7) Inhibitors in Experimental Autoimmune Encephalomyelitis Mice. Discovery of a New Chemically Diverse Family of Compounds. Journal of Medicinal Chemistry, 2012, 55, 3274-3284.	2.9	52
28	Subtly Modulating Glycogen Synthase Kinase 3 Î²: Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases. Journal of Medicinal Chemistry, 2017, 60, 4983-5001.	2.9	52
29	Inhibition of endogenous phosphodiesterase 7 promotes oligodendrocyte precursor differentiation and survival. Cellular and Molecular Life Sciences, 2013, 70, 3449-3462.	2.4	51
30	Thienylhalomethylketones: Irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools. Bioorganic and Medicinal Chemistry, 2009, 17, 6914-6925.	1.4	49
31	CoMFA of benzyl derivatives of 2,1,3-benzo and benzothieno[3,2-a]thiadiazine 2,2-dioxides: clues for the design of phosphodiesterase 7 inhibitors. European Journal of Medicinal Chemistry, 2001, 36, 333-338.	2.6	48
32	Traceless and multifunctional linkers for the generation of small molecules on solid supports. Current Opinion in Chemical Biology, 2004, 8, 230-237.	2.8	48
33	Efficient Solid-Phase Synthesis of Highly Functionalized 1,4-Benzodiazepin-5-one Derivatives and Related Compounds by Intramolecular Aza-Wittig Reactions. Chemistry - A European Journal, 2005, 11, 2680-2688.	1.7	48
34	Comparative assessment of <scp>PDE</scp> 4 and 7 inhibitors as therapeutic agents in experimental autoimmune encephalomyelitis. British Journal of Pharmacology, 2013, 170, 602-613.	2.7	48
35	Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1Î´ kinase inhibitor treatment. Scientific Reports, 2020, 10, 4449.	1.6	44
36	PDE7 inhibitors as new drugs for neurological and inflammatory disorders. Expert Opinion on Therapeutic Patents, 2008, 18, 1127-1139.	2.4	42

#	Article	IF	Citations
37	Interference of the complex between NCS-1 and Ric8a with phenothiazines regulates synaptic function and is an approach for fragile X syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E999-E1008.	3.3	40
38	Promoting in vivo remyelination with small molecules: a neuroreparative pharmacological treatment for Multiple Sclerosis. Scientific Reports, 2017, 7, 43545.	1.6	40
39	Phosphodiesterase 7 Inhibition Induces Dopaminergic Neurogenesis in Hemiparkinsonian Rats. Stem Cells Translational Medicine, 2015, 4, 564-575.	1.6	38
40	Phosphodiesterase7 Inhibition Activates Adult Neurogenesis in Hippocampus and Subventricular Zone In Vitro and In Vivo. Stem Cells, 2017, 35, 458-472.	1.4	36
41	CODES/Neural Network Model: a Useful Tool for in Silico Prediction of Oral Absorption and Blood-Brain Barrier Permeability of Structurally Diverse Drugs. QSAR and Combinatorial Science, 2004, 23, 89-98.	1.5	34
42	The Synthesis of 3-Substituted 6-Aryl-3H-benzo[a][1,2,3]triazinones Using Polymer-Bound Triazenes. ACS Combinatorial Science, 2004, 6, 38-42.	3.3	34
43	CODES, a novel procedure for ligand-based virtual screening: PDE7 inhibitors as an application example. European Journal of Medicinal Chemistry, 2008, 43, 1349-1359.	2.6	33
44	Anti-trypanosomatid benzofuroxans and deoxygenated analogues: Synthesis using polymer-supported triphenylphosphine, biological evaluation and mechanism of action studies. European Journal of Medicinal Chemistry, 2009, 44, 5055-5065.	2.6	33
45	Lessons Learnt from Glycogen Synthase Kinase 3 Inhibitors Development for Alzheimer’s Disease. Current Topics in Medicinal Chemistry, 2013, 13, 1808-1819.	1.0	31
46	5-Imino-1,2-4-thiadiazoles and quinazolines derivatives as glycogen synthase kinase 3Î² (GSK-3Î²) and phosphodiesterase 7 (PDE7) inhibitors: Determination of bloodâ€“brain barrier penetration and binding to human serum albumin. European Journal of Pharmaceutical Sciences, 2012, 45, 677-684.	1.9	30
47	<scp>PDE</scp>7 inhibitor <scp>TC</scp>3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis. British Journal of Pharmacology, 2015, 172, 4277-4290.	2.7	30
48	Kinase Inhibitors as Underexplored Antiviral Agents. Journal of Medicinal Chemistry, 2022, 65, 935-954.	2.9	30
49	Silencing phosphodiesterase 7B gene by lentiviral-shRNA interference attenuates neurodegeneration and motor deficits in hemiparkinsonian mice. Neurobiology of Aging, 2015, 36, 1160-1173.	1.5	29
50	Medicinal and Biological Chemistry (MBC) Library: An Efficient Source of New Hits. Journal of Chemical Information and Modeling, 2017, 57, 2143-2151.	2.5	28
51	Modulation of GSK-3 provides cellular and functional neuroprotection in the rd10 mouse model of retinitis pigmentosa. Molecular Neurodegeneration, 2018, 13, 19.	4.4	28
52	Protein kinase inhibitors for amyotrophic lateral sclerosis therapy. British Journal of Pharmacology, 2021, 178, 1316-1335.	2.7	28
53	Benzothiadiazine Dioxide Dibenzyl Derivatives as Potent Human Cytomegalovirus Inhibitors:â€‰ Synthesis and Comparative Molecular Field Analysis. Journal of Medicinal Chemistry, 2000, 43, 3218-3225.	2.9	27
54	Nonnucleoside Human Cytomegalovirus Inhibitors:â€‰ Synthesis and Antiviral Evaluation of (Chlorophenylmethyl)benzothiadiazine Dioxide Derivatives. Journal of Medicinal Chemistry, 2000, 43, 3267-3273.	2.9	27

#	Article	IF	Citations
55	Recent strategies in the development of new human cytomegalovirus inhibitors. Medicinal Research Reviews, 2001, 21, 227-244.	5.0	27
56	Novel Potential Agents for Human Cytomegalovirus Infection:â€‰ Synthesis and Antiviral Activity Evaluation of Benzothiadiazine Dioxide Acyclonucleosides. Journal of Medicinal Chemistry, 1999, 42, 1145-1150.	2.9	26
57	Supercritical fluid extraction of grape seeds: extract chemical composition, antioxidant activity and inhibition of nitrite production in LPS-stimulated Raw 264.7 cells. Food and Function, 2015, 6, 2607-2613.	2.1	26
58	Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis. European Journal of Medicinal Chemistry, 2021, 210, 112968.	2.6	26
59	Crosstalk between Phosphodiesterase 7 and Glycogen Synthase Kinase-3: Two Relevant Therapeutic Targets for Neurological Disorders. ACS Chemical Neuroscience, 2014, 5, 194-204.	1.7	25
60	Is drug repurposing really the future of drug discovery or is new innovation truly the way forward?. Expert Opinion on Drug Discovery, 2021, 16, 1-3.	2.5	25
61	Identification in Silico and Experimental Validation of Novel Phosphodiesterase 7 Inhibitors with Efficacy in Experimental Autoimmune Encephalomyelitis Mice. ACS Chemical Neuroscience, 2012, 3, 793-803.	1.7	24
62	Modulation of cAMP-Specific PDE without Emetogenic Activity: New Sulfide-Like PDE7 Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 8590-8607.	2.9	24
63	Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents. European Journal of Medicinal Chemistry, 2017, 138, 328-342.	2.6	24
64	A preliminary investigation of phoshodiesterase 7 inhibitor VP3.15 as therapeutic agent for the treatment of experimental autoimmune encephalomyelitis mice. Journal of Chemical Neuroanatomy, 2017, 80, 27-36.	1.0	23
65	The GSK-3-inhibitor VP2.51 produces antidepressant effects associated with adult hippocampal neurogenesis. Neuropharmacology, 2017, 116, 174-187.	2.0	23
66	Antiviral drugs targeting endosomal membrane proteins inhibit distant animal and human pathogenic viruses. Antiviral Research, 2021, 186, 104990.	1.9	23
67	Drugs in clinical development for the treatment of amyotrophic lateral sclerosis. Expert Opinion on Investigational Drugs, 2017, 26, 403-414.	1.9	22
68	Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia. European Journal of Medicinal Chemistry, 2017, 130, 60-72.	2.6	21
69	Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods. Pharmaceuticals, 2021, 14, 332.	1.7	21
70	From Bitopic Inhibitors to Multitarget Drugs for the Future Treatment of Alzheimerâ€™s Disease. Current Medicinal Chemistry, 2015, 22, 3789-3806.	1.2	21
71	Design, synthesis, and evaluation of potential inhibitors of nitric oxide synthase. Bioorganic and Medicinal Chemistry, 2008, 16, 6193-6206.	1.4	20
72	Therapeutic potential of novel Cell Division Cycle Kinase 7 inhibitors on TDPâ€43â€related pathogenesis such as Frontotemporal Lobar Degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). Journal of Neurochemistry, 2021, 156, 379-390.	2.1	20

#	Article	IF	Citations
73	TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy. Journal of Medicinal Chemistry, 2022, 65, 1585-1607.	2.9	20
74	Biology-oriented development of novel lipophilic antioxidants with neuroprotective activity. RSC Advances, 2015, 5, 15800-15811.	1.7	19
75	Small molecules targeting glycogen synthase kinase 3 as potential drug candidates for the treatment of retinitis pigmentosa. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 522-526.	2.5	19
76	Identification of Niemann-Pick C1 protein as a potential novel SARS-CoV-2 intracellular target. Antiviral Research, 2021, 194, 105167.	1.9	19
77	New insights into the role of endosomal proteins for African swine fever virus infection. PLoS Pathogens, 2022, 18, e1009784.	2.1	19
78	Microwave-assisted synthesis of hydroxyphenyl nitrones with protective action against oxidative stress. European Journal of Medicinal Chemistry, 2012, 58, 44-49.	2.6	17
79	Cyclic Nucleotide-Specific Phosphodiesterases as Potential Drug Targets for Anti-Leishmania Therapy. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	17
80	Enhancing cAMP Levels as Strategy for the Treatment of Neuropsychiatric Disorders. Current Topics in Medicinal Chemistry, 2016, 16, 3527-3535.	1.0	16
81	The new iminothiadiazole derivative VP1.14 ameliorates hippocampal damage after an excitotoxic injury. Journal of Neurochemistry, 2012, 122, 1193-1202.	2.1	15
82	Methyl jasmonate treatment of strawberry fruits enhances antioxidant activity and the inhibition of nitrite production in LPS-stimulated Raw 264.7 cells. Journal of Functional Foods, 2013, 5, 1803-1809.	1.6	15
83	Imidazole Derivatives as Promising Agents for the Treatment of Chagas Disease. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	15
84	Identification of potential inhibitors of protein-protein interaction useful to fight against Ebola and other highly pathogenic viruses. Antiviral Research, 2021, 186, 105011.	1.9	15
85	Improved Controlled Release and Brain Penetration of the Small Molecule S14 Using PLGA Nanoparticles. International Journal of Molecular Sciences, 2021, 22, 3206.	1.8	15
86	Inhibition of hippocampal long-term potentiation by high-fat diets. NeuroReport, 2017, 28, 354-359.	0.6	13
87	On the tautomerism of 2,1,3-benzothiadiazinone S,S-dioxide and related compounds. Tetrahedron, 1999, 55, 12405-12410.	1.0	12
88	Towards discovery of new leishmanicidal scaffolds able to inhibit Leishmania GSK-3. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 199-210.	2.5	12
89	Benzothiadiazine Dioxide Human Cytomegalovirus Inhibitors: Synthesis and Antiviral Evaluation of Main Heterocycle Modified Derivatives. Antiviral Chemistry and Chemotherapy, 2003, 14, 107-114.	0.3	11
90	Pharmacological tools based on imidazole scaffold proved the utility of PDE10A inhibitors for Parkinsonâ€™s disease. Future Medicinal Chemistry, 2017, 9, 731-748.	1.1	11

#	Article	IF	Citations
91	QSAR Modelling to Identify LRRK2 Inhibitors for Parkinsonâ€™s Disease. Journal of Integrative Bioinformatics, 2019, 16, .	1.0	11
92	Chlorophenylmethyl benzothiadiazine dioxides derivatives: Potent human cytomegalovirus inhibitors. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 3133-3136.	1.0	10
93	Small GSK-3 Inhibitor Shows Efficacy in a Motor Neuron Disease Murine Model Modulating Autophagy. PLoS ONE, 2016, 11, e0162723.	1.1	10
94	New applications for known drugs: Human glycogen synthase kinase 3 inhibitors as modulators of Aspergillus fumigatus growth. European Journal of Medicinal Chemistry, 2016, 116, 281-289.	2.6	10
95	Biological and Pharmacological Characterization of Benzothiazole-Based CK-1Î´ Inhibitors in Models of Parkinsonâ€™s Disease. ACS Omega, 2017, 2, 5215-5220.	1.6	10
96	Deciphering the Inhibition of the Neuronal Calcium Sensor 1 and the Guanine Exchange Factor Ric8a with a Small Phenothiazine Molecule for the Rational Generation of Therapeutic Synapse Function Regulators. Journal of Medicinal Chemistry, 2018, 61, 5910-5921.	2.9	10
97	Screening of a PDE-focused library identifies imidazoles with in vitro and in vivo antischistosomal activity. International Journal for Parasitology: Drugs and Drug Resistance, 2019, 9, 35-43.	1.4	10
98	Benzothiazole-Based LRRK2 Inhibitors as Wnt Enhancers and Promoters of Oligodendrocytic Fate. Journal of Medicinal Chemistry, 2020, 63, 2638-2655.	2.9	10
99	Potential pharmacological strategies targeting the Niemann-Pick C1 receptor and Ebola virus glycoprotein interaction. European Journal of Medicinal Chemistry, 2021, 223, 113654.	2.6	10
100	Discovery of novel Schistosoma mansoni PDE4A inhibitors as potential agents against schistosomiasis. Future Medicinal Chemistry, 2019, 11, 1703-1720.	1.1	8
101	Microwave-Assisted Solid-Phase Synthesis of a 1,2-Disubstituted Benzimidazole Library by Using a Phosphonium Linker. Journal of Heterocyclic Chemistry, 2013, 50, 720-726.	1.4	7
102	Anti-HIV-1 Activity of Benzothiadiazine Dioxide. Antiviral Chemistry and Chemotherapy, 2001, 12, 347-351.	0.3	6
103	Good oral absorption prediction on non-nucleoside benzothiadiazine dioxide human cytomegalovirus inhibitors using combined chromatographic and neuronal network techniques. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1919-1921.	1.0	6
104	Solid phase synthesis of functionalized indazoles using triazenes â€“ scope and limitations. RSC Advances, 2015, 5, 65540-65545.	1.7	6
105	Targeting PDE10A GAF Domain with Small Molecules: A Way for Allosteric Modulation with Anti-Inflammatory Effects. Molecules, 2017, 22, 1472.	1.7	6
106	Cognitive enhancement, TAU phosphorylation reduction, and neuronal protection by the treatment of an LRRK2 inhibitor in a tauopathy mouse model. Neurobiology of Aging, 2020, 96, 148-154.	1.5	6
107	Benzothiadiazine dioxides (BTD) derivatives as non-nucleoside human cytomegalovirus (HCMV) inhibitors. study of structural requirements for biological activityâ˜†. Bioorganic and Medicinal Chemistry, 2003, 11, 2395-2402.	1.4	5
108	Unraveling phosphodiesterase surfaces. Identification of phosphodiesterase 7 allosteric modulation cavities. European Journal of Medicinal Chemistry, 2013, 70, 781-788.	2.6	5

#	Article	IF	Citations
109	Phosphodiesterase Inhibitors as a New Therapeutic Approach for the Treatment of Parkinsonâ€™s Disease. RSC Drug Discovery Series, 2013, , 294-307.	0.2	5
110	Dynamics of Central Remyelination and Treatment Evolution in a Model of Multiple Sclerosis with Optic Coherence Tomography. International Journal of Molecular Sciences, 2021, 22, 2440.	1.8	4
111	Small molecule inhibitors of mammalian GSK-3Î² promote in vitro plant cell reprogramming and somatic embryogenesis in crop and forest species. Journal of Experimental Botany, 2021, 72, 7808-7825.	2.4	4
112	Naphthoquinone as a New Chemical Scaffold for Leishmanicidal Inhibitors of Leishmania GSK-3. Biomedicines, 2022, 10, 1136.	1.4	4
113	QSAR Modelling for Drug Discovery: Predicting the Activity of LRRK2 Inhibitors for Parkinsonâ€™s Disease Using Cheminformatics Approaches. Advances in Intelligent Systems and Computing, 2019, , 63-70.	0.5	3
114	Glycogen Synthase Kinase-3Î² Expression and Phosphorylation in Peripheral Blood Mononuclear Cells of Patients with Amyotrophic Lateral Sclerosis. British Journal of Medicine and Medical Research, 2014, 4, 263-271.	0.2	3
115	Organic Synthesis on Polymeric Supports. , 2005, , 137-199.		2
116	Therapeutic approaches for the future treatment of Fragile X. Current Opinion in Behavioral Sciences, 2015, 4, 6-21.	2.0	2
117	Deciphering the enzymatic target of a new family of antischistosomal agents bearing a quinazoline scaffold using complementary computational tools. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 511-523.	2.5	2
118	Discovery of Amoebicidal Compounds by Combining Computational and Experimental Approaches. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	2
119	Medicinal Chemistry Strategies to Discover New Leishmanicidal Drugs. RSC Drug Discovery Series, 2017, , 153-178.	0.2	2
120	Chapter 9. Tau Protein Kinases Inhibitors: From the Bench to the Clinical Trials. RSC Drug Discovery Series, 2010, , 173-194.	0.2	1
121	Traceless and Multifunctional Linkers for the Generation of Small Molecules on Solid Supports. ChemInform, 2005, 36, no.	0.1	0
122	Cyclic Nucleotide Phosphodiesterases and Their Role in Immunomodulatory Responses: Advances in the Development of Specific Phosphodiesterase Inhibitors. ChemInform, 2005, 36, no.	0.1	0
123	Organic Azides: An Exploding Diversity of a Unique Class of Compounds. ChemInform, 2005, 36, no.	0.1	0